While Neuralink has now secured FDA approval to commence its study, the company is not actively seeking volunteers at this stage. In a tweet on Thursday, Neuralink expressed their gratitude to the FDA and the collaborative efforts of the Neuralink team, describing the approval as an important first step toward a future where their technology can assist numerous individuals. They clarified that recruitment for their clinical trial has not yet begun.
The FDA’s approval for Neuralink to proceed with human trials signals a significant advancement in the field of brain-computer interfaces. As Neuralink continues its pioneering work, the potential for BCIs to revolutionize medical treatments and restore functionality to those with neurological conditions becomes increasingly promising.
